drugset
drugset / Trial / NCT00509756

Study Evaluating FXR-450 in Healthy Japanese Men

NCT00509756 ↗

Phase 1 Terminated 56 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedParallel-groupQuadruple-blind

Summary

The primary purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of a single dose of FXR-450 in healthy Japanese men.

Timeline

Start
2007-11
Primary completion
2008-02
Completion
2008-02

Outcome

Outcome not reported

Stopped: “Please see termination statement in the detailed description.”

Drugs

EvaluationDrugModalityDoseRoute
Comparator TUROFEXORATE ISOPROPYL Small molecule 10 mg Oral
Comparator TUROFEXORATE ISOPROPYL Small molecule 450 mg Oral

Indications

No indication recorded.